Regional Business Director – Mid-Atlantic Region - Philadelphia , PA | Biospace
Get Our FREE Industry eNewsletter

Regional Business Director – Mid-Atlantic Region

Adamas Pharmaceuticals, Inc.

Philadelphia , PA
Posted Date:
Position Type:
Full time
Job Code:
Required Education:
Bachelors Degree
Areas of Expertise Desired:

Job Description

The Regional Business Director will hire, develop and lead a high performing regional sales team of Neurology Sales Specialists. This position will help develop and then execute commercial strategies to meet Adamas national and regional business objectives. This is a field based position with corporate headquarters in Emeryville, CA.  


•   Drive an effective launch of ADS-5102 in the respective region by achieving or exceeding sales quota;
•   Hire, train and oversee the development of each assigned NSS for region;
•   Continually coach and motivate team to achieve goals through individual and team activities;
•   Analyze regional business and advise leadership on trends and strategies;
•   Plan and conduct effective regional sales meetings;
•   Administrative responsibility for region:  review and audit expense reports; prepare and manage regional budget; regional record maintenance; other administrative functions as required;
•   Assist corporate-based trainers with the development of training programs to address specific regional or individual Neurology Sales Specialist needs;
•   Partner with Marketing/Brand Team to execute brand strategy and messaging at a local level;
•   Serve as a liaison with Market Access Team;
•   Ensure Collaboration in activities within key movement disorder centers with other Adamas stakeholders;
•   Develop relationships with regional key customers;
•   Identify and propose to leadership ethical, innovative, customer-oriented tactics in response to market trends;
•   Develop appropriate cross-functional relationships to achieve corporate objectives;
•   Prepare and present reports/presentations for corporate clients, sales organization and leadership as needed;
•   Ensure compliance with corporate policies and procedures, as well as US healthcare laws and regulations.



•   Bachelor’s degree required, advanced degree preferred;
•   Minimum of 10 years’ experience in pharmaceutical industry;
•   Must have minimum 5 years’ sales leadership experience in pharmaceutical industry;
•   Demonstrated record of success with exceptional leadership and relationship building skills;
•   Experience leading specialty-focused teams required;
•   Leadership experience within Neurology preferred and Movement Disorders a significant plus;
•   Recent leadership experience during a specialty-focused launch a significant plus;
•   Excellent time management and organizational skills;
•   Must be flexible, innovative and self-motivated;
•   Strong presentation, communication and interpersonal skills;
•   Able to integrate and apply feedback in a professional manner;
•   Travel required: 50-75% of time;
•   Successful experience in fast-paced entrepreneurial environment;
•   Fit with Adamas culture and values.

Adamas Pharmaceuticals develops new medicines to improve the daily lives of those affected by chronic neurologic disorders, including Parkinson's disease, multiple sclerosis, epilepsy, and Alzheimer's disease. Adamas has pioneered a platform to develop medicines for chronic neurologic disorders based on an understanding of the time-dependent biologic processes responsible for disease activity and drug response. The company's most advanced product candidate, ADS-5102, is a high-dose amantadine, taken once-daily at bedtime, in development for the treatment of levodopa-induced dyskinesia in people with Parkinson's disease and for the treatment of walking impairment in people with multiple sclerosis. A New Drug Application supporting ADS-5102 for the treatment of levodopa-induced dyskinesia in people with Parkinson's disease is under review by the FDA with a PDUFA date of August 24, 2017. Adamas is exploring other indications for further development of ADS-5102. Adamas is also investigating ADS-4101 for the treatment of partial onset seizures in patients with epilepsy. Additionally, Adamas' licensed assets, are currently marketed by Allergan under the brand names NAMENDA XR® and NAMZARIC®, and Adamas is eligible to receive royalties on sales of these medicines beginning in June 2018 and May 2020, respectively. For more information, please visit